Medicenna Therapeutics announced that data from their Phase 1/2 ABILITY-1 study of MDNA11, a long-acting IL-2 Superkine for treating advanced cancers, will be presented orally at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting. The presentation is scheduled for Saturday, November 7, from 4:30 to 4:45 p.m. MST in Phoenix, Arizona. The study focuses on MDNA11’s efficacy as monotherapy and in combination with pembrolizumab in patients with biomarker-enriched gastrointestinal malignancies, including those resistant to immune checkpoint inhibitors (ICIs).
Written locally by qwen2.5:14b on 2026-10-05,
using this article's own text rather than the other coverage of the
same event (that is the story summary below).
Story summary
On October 5, 2026, Medicenna Therapeutics Corp., a clinical-stage immunotherapy company based in Toronto and Houston, announced that an abstract from their Phase 1/2 ABILITY-1 study of MDNA11 was selected for oral presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting. The study evaluates MDNA11, a Superkine targeting cancer and autoimmune diseases, in patients with advanced and metastatic gastrointestinal, endometrial, and melanoma cancers. The abstract will be presented on November 7, 2026, from 4:30 to 4:45 p.m. MST at the Phoenix Convention Center in Room 301D, Arizona. This presentation highlights MDNA11's clinical activity both as a monotherapy and in combination with pembrolizumab in biomarker-enriched gastrointestinal malignancies.
Written for “Medicenna Clinical Trial Results” on 2026-10-05,
grounded in this article and the 0 other(s) covering the same event.
The Phase 1/2 ABILITY-1 Clinical Trial is evaluating MDNA11 in expansion cohorts comprised of patients with advanced and metastatic gastrointestinal, endometrial, and melanoma cancers
Selected as one of the Top 150 Abstracts at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting
TORONTO and HOUSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting cancer and autoimmune disease, today announced that an abstract reporting topline data from the Phase 1/2 study of MDNA11 has been selected for oral presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting.
asserted
abstract → evaluate → Meeting
Details of the oral presentation are as follows:
asserted
Details → follow → presentation
Abstract Number: 517
Presentation Type: Oral Presentation
Presentation Date: Saturday, November 7, 2026
Presentation Time: 4:30-4:45 p.m. MST
Session: Oral Session 3, 3:30-4:50 p.m. MST
Location: Phoenix Convention Center, Room 301D, Phoenix, Arizona
Title: “MDNA11 Demonstrates Clinical Activity as Monotherapy and in Combination with Pembrolizumab in Biomarker-Enriched Gastrointestinal Malignancies, Including ICI-Refractory Disease.”
asserted
MDNA11 → demonstrate → Disease
Medicenna is a clinical-stage immunotherapy company developing engineered cytokine therapies designed to selectively engage the immune system to treat cancer.
asserted
Medicenna → develop → cancer
The Company’s most advanced program, bizaxofusp (formerly MDNA55), is a targeted IL-4 Empowered Superkine that has been evaluated in more than 130 patients across five clinical trials, including a Phase 2b study in recurrent glioblastoma.
asserted
that → target → glioblastoma
Bizaxofusp has received Fast Track designation from the FDA and Orphan Drug designation in the United States and Europe.
asserted
Bizaxofusp → receive → States
Medicenna is also advancing MDNA11, a long-acting IL-2 Superkine designed to selectively activate cancer-fighting immune cells, which is currently being evaluated in the Phase 1/2 ABILITY-1 study and the Phase 1b NEO-CYT study.
asserted
which → advance → study
The Company is also developing MDNA113, a targeted PD-1 x IL-2 bifunctional immunotherapy for solid tumors, and MDNA209, an antagonist of CD122 blocking IL-2/IL-15 signaling, using its proprietary BiSKIT and T-MASK platforms.
asserted
Company → develop → platforms
This news release contains forward-looking statements within the meaning of applicable securities laws.
asserted
release → contain → laws
Forward-looking statements include, but are not limited to, express or implied statements regarding the future operations of the Company, estimates, plans, strategic ambitions, partnership activities and opportunities, objectives, expectations, opinions, forecasts, projections, guidance, outlook or other statements that are not historical facts.
asserted
that → look → Company
Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expect”, “believe”, “seek”, “potentially” and similar expressions.
uncertain
statements → look → will
There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.
uncertain
results → prove → statements
Important factors that could cause actual results to differ materially from the Company’s expectations include the risks detailed in the latest annual information form of the Company and in other filings made by the Company with the applicable securities regulators from time to time in Canada.
uncertain
results → cause → Canada
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect.
uncertain
assumptions → caution → information
Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company.
uncertain
many → cause → Company
The reader is cautioned not to place undue reliance on any forward-looking information.
asserted
reader → caution → information
Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated.
uncertain
results → consider → those
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
asserted
statements → look → statement
The forward-looking statements contained in this news release are made as of the date hereof and except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements.
asserted
we → look → statements
This news release contains hyperlinks to information that is not deemed to be incorporated by reference in this new release.
asserted
that → contain → release
The Aporia
